AI-generated analysis. Always verify with the original filing.
Corvus Pharmaceuticals, Inc. filed an 8-K on March 12, 2026, under Item 2.02 disclosing results of operations via Exhibit 99.1 press release, which is not deemed 'filed' for Section 18 purposes. The filing includes Item 9.01 listing the press release as Exhibit 99.1 and Cover Page Interactive Data as Exhibit 104.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release of Corvus Pharmaceuticals, Inc. dated March 12, 2026. 104 Cover Page Interactive